Accelerating cures through venture philanthropy

Venture philanthropy. It’s a buzz phrase going around and gaining ground in the nonprofit arena. Early last month, LLS announced an exciting new venture philanthropy partnership with Celgene Corporation, the makers of Revlimid, a drug for multiple myeloma.

So what are we talking about here?

Venture philanthropy brings concepts and techniques from venture capital finance and high tech business management together and applies them in support of a philanthropic goal. In this case, our mission to cure blood cancers and improve the quality of life for patients and their families.

Venture philanthropy has some common “characteristics:”

  • There’s a willingness to try new approaches
  • There’s a focus on measurable results or benchmarks
  • Funding on a multi-year basis

LLS’s new partnership with Celgene is designed to accelerate innovative research in areas with significant unmet medical need and advance our understanding of blood cancer biology.  The blending of cutting-edge academic science with pharmaceutical company resources yields new, life-saving therapies. For blood cancer patients it means more opportunities to give thanks, more holiday cheer with family and friends and more New Years’ Eve countdowns.


About Megan Kilkenny

LLS Sr. Director, Marketing Communication Team In Training Alum Three-time Nike Women's Half Marathon finisher
This entry was posted in Blood Cancer Research, LLS Partners and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s